NCT02688491View on ClinicalTrials.gov

A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment

NANot yet recruitingINTERVENTIONAL

Enrollment

300

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

Renal NeoplasmsTargeted Molecular Therapy

Interventions

DRUG

sunitinib

The investigators randomly assign assay-defined high risk patients of stageIII ccRCC into intervention group and observation group. The intervention group should receive adjuvant targeted therapy while the control group deserve observation.

All Listed Sponsors

collaborator

Xi'an Jiaotong University

OTHER

collaborator

Yantai Yuhuangding Hospital

OTHER

collaborator

Sun Yat-sen University

OTHER

lead

First Affiliated Hospital, Sun Yat-Sen University

OTHER

NCT02688491 - A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment | Biotech Hunter | Biotech Hunter